HomeTOP STORIESCancer drug developer BlossomHill slips after upsized IPO Cancer drug developer BlossomHill slips after upsized IPO By rogerjudd August 7, 2026 FacebookTwitterPinterestWhatsApp Post Content Previous articleLabor Market Shifts Into Reverse as Employers Balk at HiringNext articleJFrog jumps 7% on strong earnings, upgraded FY26 outlook latest articles SUI Group outlines 5%-6% Bluefin loan yield through Sep 2028 as treasury reaches 109M SUI Fidus outlines Q3 2026 total dividend of $0.50 per share as deal flow “picking up” into Q4 Photos Show England Turning Brown in Drought A Drying Danube River Reveals Nazi-Era Vessels, and Hazards of Heat JFrog jumps 7% on strong earnings, upgraded FY26 outlook Labor Market Shifts Into Reverse as Employers Balk at Hiring explore more SUI Group outlines 5%-6% Bluefin loan yield through Sep 2028 as treasury reaches 109M SUI Fidus outlines Q3 2026 total dividend of $0.50 per share as deal flow “picking up” into Q4 Photos Show England Turning Brown in Drought A Drying Danube River Reveals Nazi-Era Vessels, and Hazards of Heat JFrog jumps 7% on strong earnings, upgraded FY26 outlook Labor Market Shifts Into Reverse as Employers Balk at Hiring
